Dr. Maged Khalil, MD

Dr. Khalil practices at Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University.

Dr. Khalil's NPI, 1366578429, was assigned on February 25, 2007. Dr. Khalil holds Pennsylvania license MD422406.

Dr. Khalil's primary practice is Lehigh Valley Hospital-Cedar Crest, at 1200 South Cedar Crest Boulevard, Allentown, PA 18103 in Lehigh County. The practice phone is (610) 402-8000.

Dr. Khalil's primary practice is Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University. Dr. Khalil is also affiliated with Lehigh Valley Hospital-Pocono. The medical group on file is Geisinger. Dmand AI also links Dr. Khalil to 3 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khalil practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Khalil's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Khalil is licensed in Pennsylvania.

CMS data shows 677 Medicare services from Dr. Khalil across 5 procedure codes in 2024, for 241 Medicare patients. Medicare paid $66,589 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 241 Medicare patients who saw Dr. Khalil in 2024. The largest group is 65 to 74, with 123 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 9% are also on Medicaid. Their average risk score is 2.16, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khalil's median patient age at 67, with 48% women.

In 2024, Dr. Khalil wrote 458 Medicare Part D claims for 121 patients. 70% of them were for generic drugs. CMS names the drug for 332 of them, across 11 drugs with 11 or more claims each, at $1,322,859 in total drug cost. In 2023, CMS named 214 claims across 9 drugs.

Dr. Khalil accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Khalil, published from 2012 to 2024. 2020 was the busiest year, with 2. The most frequent topics are Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols and Cisplatin. Dr. Khalil's most frequent co-authors are Arjun Vasant Balar, MD, Timothy L. Cannon, MD and Richard L. Schilsky, MD.

Dmand AI links Dr. Khalil to 1 clinical trial. 1 is still active or recruiting.

CMS Open Payments shows 24 general payments to Dr. Khalil from 11 drug and device companies from 2016 to 2023. Consulting fees make up the largest share, 88% of the total. Bristol-Myers Squibb Company paid the most, $4,800.